Challenges in searching for therapeutics against Botulinum Neurotoxins

Expert Opinion on Drug Discovery

Volumn 12, Issue 5, 2017, Pages 497-510

  Pirazzini, Marco ^a   Rossetto, Ornella ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

bioterrorism; bioweapon; Botulinum Neurotoxins; clostridium; neuromuscular junction; neuroparalysis; pan inhibitors; serotypes; subtypes; thioredoxin

Indexed keywords

ANTIDOTE; BOTULINUM TOXIN; PROTEINASE; SNARE PROTEIN; BOTULINUM ANTISERUM; NEUROTOXIN;

CHANNEL GATING; CYTOSOL; DISULFIDE BOND; DRUG INTOXICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENDOSOME; NERVE ENDING; NEUROMUSCULAR JUNCTION; NEUROTOXICITY; NONHUMAN; PARALYSIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; REVIEW; THERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; BOTULISM; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; PATHOLOGY; PROCEDURES;

ANIMALS; ANTIDOTES; BOTULINUM ANTITOXIN; BOTULINUM TOXINS; BOTULISM; DRUG DESIGN; DRUG DISCOVERY; HUMANS; NEUROMUSCULAR JUNCTION; NEUROTOXINS;

EID: 85016594121     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2017.1303476     Document Type: Review

References (167)

1. Rossetto O, Pirazzini M, Montecucco C., Botulinum neurotoxins:genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535–549.
2. Williamson CH, Sahl JW, Smith TJ, et al. Comparative genomic analyses reveal broad diversity in botulinum-toxin-producing Clostridia. BMC Genomics. 2016;17:180.
3. Johnson EA, Montecucco C. Botulism. Handb Clin Neurol. 2008;91:333–368.• This is a remarkable review illustrating the general aspects of botulism.
4. De Spain Smith L, Sugiyama H. Botulism:the organism, its toxins, the disease. Springfield, Illinois:Charles C. Thomas Publisher; 1988.
5. Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998;21:701–710.
6. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon:medical and public health management. Jama. 2001;285:1059–1070.
7. Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). Possession, use, and transfer of select agents and toxins; biennial review. Final Rule Federal Register. 2012;77:61083–61115.
8. Lam K-H, Jin R. Architecture of the botulinum neurotoxin complex:a molecular machine for protection and delivery. Curr Opin Struct Biol. 2015;31:89–95.
9. Fujinaga Y, Sugawara Y, Matsumura T. Uptake of botulinum neurotoxin in the intestine. Curr Top Microbiol Immunol. 2013;364:45–59.
10. Koepke R, Sobel J, Arnon SS. Global occurrence of infant botulism, 1976-2006. Pediatrics. 2008;122:e73–82.
11. Peck MW, Smith TJ, Anniballi F, et al. Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins (Basel). 2017;9:38.
12. Smith TJ, Hill KK, Raphael BH. Historical and current perspectives on Clostridium botulinum diversity. Res Microbiol. 2015;166:290–302.
13. Montecucco C, Rasotto MB. On botulinum neurotoxin variability. MBio. 2015;6:e02131-14.
14. Lacy DB, Tepp W, Cohen AC, et al. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol. 1998;5:898–902.•• This article was the first to report the crystal structure of BoNT and provides the molecular basis for understanding the mechanism of neuron intoxication.
15. Rummel A. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity. Curr Top Microbiol Immunol. 2013;364:61–90.
16. Antonucci F, Rossi C, Gianfranceschi L, et al. Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci. 2008;28:3689–3696.
17. Coelho A, Cruz F, Cruz CD, et al. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol. 2012;61:1178–1184.
18. Coelho A, Dinis P, Pinto R, et al. Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder. Eur Urol. 2010;57:884–890.
19. Montal M. Botulinum neurotoxin:a marvel of protein design. Annu Rev Biochem. 2010;79:591–617.
20. Pirazzini M, Tehran DA, Leka O, et al. On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments. Biochim Biophys Acta. 2016;1858(3):467–474.
21. Pantano S, Montecucco C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell Mol Life Sci. 2014;71(5):793–811.
22. Binz T. Clostridial neurotoxin light chains:devices for SNARE cleavage mediated blockade of neurotransmission. Curr Top Microbiol Immunol. 2013;364:139–157.
23. Binz T, Rummel A. Cell entry strategy of clostridial neurotoxins. J Neurochem. 2009;109:1584–1595.
24. Montecucco C, Rossetto O, Schiavo G. Presynaptic receptor arrays for clostridial neurotoxins. Trends Microbiol. 2004;12:442–446.
25. Kammerer RA, Benoit RM. Botulinum neurotoxins:new questions arising from structural biology. Trends Biochem Sci. 2014;39:517–526.
26. Jacky BPS, Garay PE, Dupuy J, et al. Identification of fibroblast growth factor receptor 3 (FGFR3) as a protein receptor for botulinum neurotoxin serotype A (BoNT/A). Plos Pathog. 2013;9:e1003369.
27. Li X, Coffield JA. Structural and functional interactions between transient receptor potential vanilloid subfamily 1 and botulinum neurotoxin serotype A. Plos One. 2016;11:e0143024.
28. Montecucco C. How do tetanus and botulinum toxins bind to neuronal membranes?. Trends Biochem Sci. 1986;11:314–317.• This paper proposed the dual receptor model for the binding of BoNT to neuronal membranes.
29. Colasante C, Rossetto O, Morbiato L, et al. Botulinum Neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction. Mol Neurobiol. 2013;48:120–127.
30. Harper CB, Martin S, Nguyen TH, et al. Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism. J Biol Chem. 2011;286:35966–35976.• This study reported the first demonstration that the internalization of BoNTs may be a target to develop inhibitors.
31. Harper CB, Papadopulos A, Martin S, et al. Botulinum neurotoxin type-A enters a non-recycling pool of synaptic vesicles. Sci Rep. 2016;6:19654.
32. Willig KI, Rizzoli SO, Westphal V, et al. STED microscopy reveals that synaptotagmin remains clustered after synaptic vesicle exocytosis. Nature. 2006;440:935–939.
33. Kaempf N, Kochlamazashvili G, Puchkov D, et al. Overlapping functions of stonin 2 and SV2 in sorting of the calcium sensor synaptotagmin 1 to synaptic vesicles. Proc Nat Acad Sci USA. 2015;112:7297–7302.
34. Wang T, Martin S, Papadopulos A, et al. Control of autophagosome axonal retrograde flux by presynaptic activity unveiled using botulinum neurotoxin type a. J Neurosci. 2015;35:6179–6194.
35. Pellett S, Tepp WH, Scherf JM, et al. Botulinum Neurotoxins can enter cultured neurons independent of synaptic vesicle recycling. Plos One. 2015;10:e0133737.
36. Simpson LL. Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins. J Pharmacol Exp The. 1983;225:546–552.
37. Keller JE, Cai F, Neale EA. Uptake of botulinum neurotoxin into cultured neurons. Biochemistry. 2004;43:526–532.
38. Sun S, Suresh S, Liu H, et al. Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly. Cell Host Microbe. 2011;10:237–247.
39. Pirazzini M, Rossetto O, Bolognese P, et al. Double anchorage to the membrane and intact inter-chain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons. Cell Microbiol. 2011;13:1731–1743.
40. Pirazzini M, Henke T, Rossetto O, et al. Neutralisation of specific surface carboxylates speeds up translocation of botulinum neurotoxin type B enzymatic domain. FEBS Lett. 2013;587:3831–3836.
41. Koriazova LK, Montal M. Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat Struct Biol. 2003;10:13–18.
42. Montecucco C, Schiavo G, Dasgupta BR. Effect of pH on the interaction of botulinum neurotoxins A, B and E with liposomes. Biochem J. 1989;259:47–53.
43. Fischer A, Montal M. Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function. Toxicon. 2013;1(75):101–107.
44. Fischer A, Montal M. Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes. J Biol Chem. 2007;282:29604–29611.•• This study showed that translocation of the L chain is associated with L chain unfolding and is concluded with disulfide bridge reduction.
45. Chellappan G, Kumar R, Santos E, et al. Structural and functional analysis of botulinum neurotoxin subunits for pH-dependent membrane channel formation and translocation. Biochim Biophys Acta. 2015;1854:1510–1516.
46. Pirazzini M, Bordin F, Rossetto O, et al. The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals. FEBS Lett. 2013;587:150–155.•• This study was the first reporting that the TrxR-Trx system is involved in the nerve terminal entry of BoNTs and TeNT
47. Pirazzini M, Azarnia Tehran D, Zanetti G, et al. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins. Cell Rep. 2014;8:1870–1878.
48. Zanetti G, Azarnia Tehran D, Pirazzini M, et al. Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism. Biochem Pharmacol. 2015;98(3):522–530.
49. Azarnia Tehran D, Pirazzini M, Leka O, et al. Hsp90 is involved in the entry of clostridial neurotoxins into the cytosol of nerve terminals. Cell Microbiol. 2017;19:2.
50. Brunger AT, Rummel A. Receptor and substrate interactions of clostridial neurotoxins. Toxicon. 2009;54:550–560.
51. Agarwal R, Schmidt JJ, Stafford RG, et al. Mode of VAMP substrate recognition and inhibition of Clostridium botulinum neurotoxin F. Nat Struct Mol Bio. 2009;16:789–794.
52. Breidenbach MA, Brunger AT. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature. 2004;432:925–929.
53. Karalewitz -AP-A, Barbieri JT. Vaccines against botulism. Curr Opin Microbiol. 2012;15:317–324.
54. Webb RP, Smith TJ, Wright P, et al. Production of catalytically inactive BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against toxin subtypes A1, A2, and A3. Vaccine. 2009;27:4490–4497.
55. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep. 2010;59:299.
56. Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354:462–471.• This article was the first to report the use of a human antiserum against BoNTs.
57. Adekar SP, Takahashi T, Jones RM, et al. Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain. Plos One. 2008;3:e3023.
58. Garcia-Rodriguez C, Levy R, Arndt JW, et al. Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol. 2007;25:107–116.
59. Razai A, Garcia-Rodriguez C, Lou J, et al. Molecular evolution of antibody affinity for sensitive detection of botulinum neurotoxin Type A. J Mol Biol. 2005;351:158–169.
60. Garcia-Rodriguez C, Geren IN, Lou J, et al. Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin. Protein Eng Des Sel. 2011;24:321–331.
61. Sepulveda J, Mukherjee J, Tzipori S, et al. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding Agents. Infect Immun. 2010;78:756–763.
62. Tremblay JM, Kuo CL, Abeijon C, et al. Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases. Toxicon. 2010;56:990–998.
63. Dong J, Thompson AA, Fan Y, et al. A single-domain llama antibody potently inhibits the enzymatic activity of botulinum neurotoxin by binding to the non-catalytic alpha-exosite binding region. J Mol Biol. 2010;397:1106–1118.
64. Bakherad H, Mousavi Gargari SL, Rasooli I, et al. In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH). Mol Biotechnol. 2013;55:159–167.
65. Eswaramoorthy S, Kumaran D, Swaminathan S. Crystallographic evidence for doxorubicin binding to the receptor-binding site in Clostridium botulinum neurotoxin B. Acta Crystallogr D Biol Crystallogr. 2001;57:1743–1746.
66. Cai S, Singh BR. Strategies to design inhibitors of Clostridium botulinum neurotoxins. Infect Disord Drugtarg. 2007;7:47–57.
67. Bakry N, Kamata Y, Simpson LL. Lectins from Triticum vulgaris and Limax flavus are universal antagonists of botulinum neurotoxin and tetanus toxin. J Pharm Exp Ther. 1991;258:830–836.
68. Kalandakanond S, Coffield JA. Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J Pharm Exp Ther. 2001;296:980–986.
69. Azarnia Tehran D, Zanetti G, Leka O, et al. A novel inhibitor prevents the peripheral neuroparalysis of Botulinum Neurotoxins. Sci Rep. 2015;5:17513.
70. Simpson LL. The interaction between aminoquinolines and presynaptically acting neurotoxins. J Pharmacol Exp Ther. 1982;222:43–48.•• This article was first to report that the blockade of endocytic compartments inhibits the action of BoNTs.
71. Sheridan RE, Deshpande SS, Nicholson JD, et al. Structural features of aminoquinolines necessary for antagonist activity against botulinum neurotoxin. Toxicon. 1997;35:1439–1451.
72. Montgomery VA, Ahmed SA, Olson MA, et al. Ex vivo inhibition of Clostridium botulinum neurotoxin types B, C, E, and F by small molecular weight inhibitors. Toxicon. 2015;98:12–19. [Epub 2015 0225].
73. Simpson LL, Coffield JA, Bakry N. Inhibition of vacuolar adenosine triphosphatase antagonizes the effects of clostridial neurotoxins but not phospholipase A2 neurotoxins. J Pharmacol Exp Ther. 1994;269:256–262.
74. Sheridan RE. Protonophore antagonism of botulinum toxin in mouse muscle. Toxicon. 1996;34:849–855.
75. Shi YL, Li MF. Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine. Progr Neurobiol. 2007;82:1–10.
76. Zhou JY, Wang ZF, Ren XM, et al. Antagonism of botulinum toxin type A-induced cleavage of SNAP-25 in rat cerebral synaptosome by toosendanin. FEBS Lett. 2003;555:375–379.
77. Li MF, Shi YL. Toosendanin interferes with pore formation of botulinum toxin type A in PC12 cell membrane. Acta Pharmacol Sin. 2006;27:66–70.
78. Fischer A, Nakai Y, Eubanks LM, et al. Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A. 2009;106:1330–1335.•• This study describes a sophisticated experimental approach to investigate BoNT translocation at single molecule resolution through which authors proposed a double mechanism of action for the drug toosendanin
79. Nakai Y, Tepp WH, Dickerson TJ, et al. Function-oriented synthesis applied to the anti-botulinum natural product toosendanin. Bioorg Med Chem. 2009;17:1152–1157.
80. Nakai Y, Pellett S, Tepp WH, et al. Toosendanin:synthesis of the AB-ring and investigations of its anti-botulinum properties (Part II). Bioorg Med Chem. 2010;18:1280–1287.
81. Seki H, Xue S, Pellett S, et al. Cellular Protection of SNAP-25 against botulinum neurotoxin/A:inhibition of thioredoxin reductase through a suicide substrate mechanism. J Am Chem Soc. 2016;138:5568–5575.
82. Silhar P, Silvaggi NR, Pellett S, et al. Evaluation of adamantane hydroxamates as botulinum neurotoxin inhibitors:synthesis, crystallography, modeling, kinetic and cellular based studies. Bioorg Med Chem. 2013;21:1344–1348.
83. Pang YP, Davis J, Wang S, et al. Small molecules showing significant protection of mice against botulinum neurotoxin serotype A. Plos One. 2010;5:e10129. [Epub 2010 0421].
84. Pang YP, Vummenthala A, Mishra RK, et al. Potent new small-molecule inhibitor of botulinum neurotoxin serotype A endopeptidase developed by synthesis-based computer-aided molecular design. Plos One. 2009;4:e7730.
85. Roxas-Duncan V, Enyedy I, Montgomery VA, et al. Identification and biochemical characterization of small-molecule inhibitors of clostridium botulinum neurotoxin serotype A. Antimicrob Ag Chemoth. 2009;53:3478–3486.
86. Bremer PT, Adler M, Phung CH, et al. Newly designed quinolinol inhibitors mitigate the effects of botulinum neurotoxin A in enzymatic, cell-based, and ex vivo assays. J Med Chem. 2017;60:338–348.
87. Silhar P, Capkova K, Salzameda NT, et al. Botulinum neurotoxin A protease:discovery of natural product exosite inhibitors. J Am Chem Soc. 2010;132:2868–2869.
88. Eubanks LM, Silhar P, Salzameda NT, et al. Identification of a natural product antagonist against the botulinum neurotoxin light chain protease. ACS Med Chem Lett. 2010;1:268–272.
89. Schiavo G, Poulain B, Rossetto O, et al. Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. Embo J. 1992;11:3577–3583.
90. Adler M, Nicholson JD, Cornille F, et al. Efficacy of a novel metalloprotease inhibitor on botulinum neurotoxin B activity. FEBS Lett. 1998;429:234–238.
91. Adler M, Nicholson JD, Starks DF, et al. Evaluation of phosphoramidon and three synthetic phosphonates for inhibition of botulinum neurotoxin B catalytic activity. J Appl Toxicol. 1999;19(Suppl 1):S5–s11.
92. Zuniga JE, Schmidt JJ, Fenn T, et al. A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure. 2008;16:1588–1597.
93. Anne C, Turcaud S, Quancard J, et al. Development of potent inhibitors of botulinum neurotoxin type B. J Med Chem. 2003;46:4648–4656. [Epub 2003 1017].
94. Anne C, Turcaud S, Blommaert AG, et al. Partial protection against botulinum B neurotoxin-induced blocking of exocytosis by a potent inhibitor of its metallopeptidase activity. Chembiochem. 2005;6:1375–1380.
95. Tsai YC, Maditz R, Kuo C-L, et al. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci USA. 2010;107:16554–16559.• This article reported for the first time how BoNT L chain are degraded within cells, providing a strong rational for the development of new type of antitoxins.
96. Kuo C-L, Oyler GA, Shoemaker CB. Accelerated neuronal cell recovery from botulinum neurotoxin intoxication by targeted ubiquitination. Plos One. 2011;6:e20352.
97. Ferrer-Montiel AV, Canaves JM, DasGupta BR, et al. Tyrosine phosphorylation modulates the activity of clostridial neurotoxins. J Biol Chem. 1996;271:18322–18325.
98. Ibanez C, Blanes-Mira C, Fernandez-Ballester G, et al. Modulation of botulinum neurotoxin A catalytic domain stability by tyrosine phosphorylation. FEBS Lett. 2004;578:121–127.
99. Kiris E, Burnett JC, Nuss JE, et al. SRC family kinase inhibitors antagonize the toxicity of multiple serotypes of botulinum neurotoxin in human embryonic stem cell-derived motor neurons. Neurotoxi Res. 2015;27:384–398.
100. Kiris E, Nuss JE, Stanford SM, et al. Phosphatase inhibitors function as novel, broad spectrum botulinum neurotoxin antagonists in mouse and human embryonic stem cell-derived motor neuron-based assays. Plos One. 2015;10:e0129264.• Articles 146 and 147 reported remarkable observations that BoNT activity can be modulated by interfering with intracellular host factors.
101. Molgo J, Lemeignan M, Thesleff S. Aminoglycosides and 3,4-diaminopyridine on neuromuscular block caused by botulinum type A toxin. Muscle Nerve. 1987;10:464–470.
102. Harris TL, Lowery CA, Hixon MS, et al. A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity. ACS Chem Neurosci. 2014;5:632–636.
103. Adler M, Deshpande SS, Apland JP, et al. Reversal of BoNT/A-mediated inhibition of muscle paralysis by 3,4-diaminopyridine and roscovitine in mouse phrenic nerve-hemidiaphragm preparations. Neurochem Internat. 2012;61:866–873.
104. Shen J, Ma J, Lee C, et al. How muscles recover from paresis and atrophy after intramuscular injection of botulinum toxin A:study in juvenile rats. J Orthop Res. 2006;24:1128–1135.
105. Simpson L. The life history of a botulinum toxin molecule. Toxicon. 2013;68:40–59.• This article is a remarkable review illustrating the long journey of a BoNT molecule inside the host.
106. Ravichandran E, Gong Y, Al Saleem FH, et al. An initial assessment of the systemic pharmacokinetics of botulinum toxin. J Pharmacol Exp Ther. 2006;318:1343–1351.
107. Al-Saleem FH, Ancharski DM, Ravichandran E, et al. The role of systemic handling in the pathophysiologic actions of botulinum toxin. J Pharmacol Exp Ther. 2008;326:856–863.
108. Dolimbek BZ, Aoki KR, Steward LE, et al. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007;44:1029–1041.
109. Maruta T, Dolimbek BZ, Aoki KR, et al. Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes:a new assay for blocking and non-blocking antibodies. J Neurosci Methods. 2006;151:90–96.
110. Fischer A, Montal M. Single molecule detection of intermediates during botulinum neurotoxin translocation across membranes. Proc Natl Acad Sci U S A. 2007;104:10447–10452.
111. Fan Y, Dong J, Lou J, et al. Monoclonal antibodies that inhibit the proteolytic activity of botulinum neurotoxin serotype/B. Toxins. 2015;7:3405–3423.
112. Fan Y, Geren IN, Dong J, et al. Monoclonal antibodies targeting the alpha-exosite of botulinum neurotoxin serotype/A inhibit catalytic activity. Plos One. 2015;10:e0135306.
113. Miethe S, Mazuet C, Liu Y, et al. Development of germline-humanized antibodies neutralizing Botulinum Neurotoxin A and B. Plos One. 2016;11:e0161446.
114. http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM345147.pdf.
115. Nowakowski A, Wang C, Powers DB, et al. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA. 2002;99:11346–11350.•• This article was the first to report that monoclonal antibodies may be used to neutralize BoNT activity.
116. Lou J, Geren I, Garcia-Rodriguez C, et al. Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating. Protein Eng Des Sel. 2010;23:311–319.
117. Yao G, Zhang S, Mahrhold S, et al.N-linked glycosylation of SV2 is required for binding and uptake of botulinum neurotoxin A. Nat Struct Mol Biol. 2016;23:656–662.
118. Mahrhold S, Bergstrom T, Stern D, et al. Only the complex N559-glycan in the synaptic vesicle glycoprotein 2C mediates high affinity binding to botulinum neurotoxin serotype A1. Biochem J. 2016;473:2645–2654.•• Articles 74 and 75 report that BoNT/A interacts with its receptor also via protein–glycan interaction that can be a target for toxin inhibition.
119. Seki H, Xue S, Hixon MS, et al. Toward the discovery of dual inhibitors for botulinum neurotoxin A:concomitant targeting of endocytosis and light chain protease activity. Chem Comm (Camb). 2015;51:6226–6229.• This article was the first to report that a small molecule drug may target more than one functional aspect of BoNTs, providing concomitant inhibition of multiple steps of their mechanism of action.
120. Gillespie EJ, Ho C-LC, Balaji K, et al. Selective inhibitor of endosomal trafficking pathways exploited by multiple toxins and viruses. Proc Nat Acad Sci USA. 2013;110:E4904–12.
121. Fagan RP, McLaughlin JB, Middaugh JP. Persistence of botulinum toxin in patients’ serum:alaska, 1959-2007. J Inf Dis. 2009;199:1029–1031.
122. Casey JR, Grinstein S, Orlowski J. Sensors and regulators of intracellular pH. Nature Rev Mol Cell Biol. 2010;11:50–61.
123. Pirazzini M, Rossetto O, Bertasio C, et al. Time course and temperature dependence of the membrane translocation of tetanus and botulinum neurotoxins C and D in neurons. Biochem Biophys Res Commun. 2013;430:38–42.
124. Shi YL, Wang ZF. Cure of experimental botulism and antibotulismic effect of toosendanin. Acta Pharmacol Sin. 2004;25:839–848.
125. Li MF, Wu Y, Wang ZF, et al. Toosendanin, a triterpenoid derivative, increases Ca2+ current in NG108-15 cells via L-type channels. Neurosci Res. 2004;49:197–203.
126. Li B, Peet NP, Butler MM, et al. Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules. 2010;16:202–220.
127. Fischer A. Synchronized chaperone function of botulinum neurotoxin domains mediates light chain translocation into neurons. Curr Top Microbiol Immunol. 2013;364:115–137.
128. Ratts R, Zeng H, Berg EA, et al. The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complex. J Cell Biol. 2003;160:1139–1150.
129. Saibil H. Chaperone machines for protein folding, unfolding and disaggregation. Nature Rev Mol Cell Biol. 2013;14:630–642.
130. Sreedhar AS, Kalmar E, Csermely P, et al. Hsp90 isoforms:functions, expression and clinical importance. FEBS Lett. 2004;562:11–15.
131. Hanschmann EM, Godoy JR, Berndt C, et al. Thioredoxins, glutaredoxins, and peroxiredoxins-molecular mechanisms and health significance:from cofactors to antioxidants to redox signaling. Antiox Redox Signal. 2013;19:1539–1605.
132. Tonissen KF, Di Trapani G. Thioredoxin system inhibitors as mediators of apoptosis for cancer therapy. Mol Nutr Food Res. 2009;53:87–103.
133. Zhao R, Masayasu H, Holmgren A. Ebselen:a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proc Natl Acad Sci USA. 2002;99:8579–8584.
134. Montal M. Redox regulation of botulinum neurotoxin toxicity:therapeutic implications. Trends Mol Med. 2014;20:602–603.
135. Kiris E, Burnett JC, Kane CD, et al. Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem. 2014;14:2044–2061.•• This is a very comprehensive review of the recent advances in BoNT inhibitor research developments.
136. Li B, Pai R, Cardinale SC, et al. Synthesis and biological evaluation of botulinum neurotoxin A protease inhibitors. J Med Chem. 2010;53:2264–2276.
137. Boldt GE, Kennedy JP, Janda KD. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Organic Letters. 2006;8:1729–1732.
138. Eubanks LM, Hixon MS, Jin W, et al. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci USA. 2007;104:2602–2607.
139. Silvaggi NR, Boldt GE, Hixon MS, et al. Structures of Clostridium botulinum neurotoxin serotype a light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol. 2007;14:533–542.• This article reports the first cocrystal structure of BoNT/A1 with a small-molecule inhibitor.
140. Duplantier AJ, Kane CD, Bavari S. Searching for therapeutics against botulinum neurotoxins:a true challenge for drug discovery. Curr Top Med Chem. 2016;16:2330–2349.
141. Kumar G, Agarwal R, Swaminathan S. Discovery of a fluorene class of compounds as inhibitors of botulinum neurotoxin serotype E by virtual screening. Chem Commun. 2012;48:2412–2414.
142. Rossetto O, Schiavo G, Montecucco C, et al. SNARE motif and neurotoxins. Nature. 1994;372:415–416.• This article was first to report the identification of a common recognition motif in SNARE proteins.
143. Chen S. Clostridial neurotoxins:mode of substrate recognition and novel therapy development. Curr Prot Pept Sci. 2014;15:490–503.
144. Kumaran D, Rawat R, Ludivico ML, et al. Structure- and substrate-based inhibitor design for Clostridium botulinum neurotoxin serotype A. J Biol Chem. 2008;283:18883–18891.
145. Kumaran D, Rawat R, Ahmed SA, et al. Substrate binding mode and its implication on drug design for botulinum neurotoxin A. Plos Pathog. 2008;4:e1000165.• Article 139 and 130 provided detailed information on the enzyme/substrate critical interactions for designing substrate-based inhibitors.
146. Chen S, Barbieri JT. Unique substrate recognition by botulinum neurotoxins serotypes A and E. J Biol Chem. 2006;281:10906–10911.
147. Schmidt JJ, Stafford RG. A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett. 2002;532:423–426.
148. Hale M, Oyler G, Swaminathan S, et al. Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J Biol Chem. 2011;286:1802–1811.
149. Blommaert A, Turcaud S, Anne C, et al. Small tripeptide surrogates with low nanomolar affinity as potent inhibitors of the botulinum neurotoxin B metallo-proteolytic activity. Bioorg Med Chem. 2004;12:3055–3062.
150. Eleopra R, Tugnoli V, Quatrale R, et al. Different types of botulinum toxin in humans. Mov Disord. 2004;19:S53–9.
151. Keller JE, Neale EA, Oyler G, et al. Persistence of botulinum neurotoxin action in cultured spinal cord cells. FEBS Lett. 1999;456:137–142.
152. Whitemarsh RC, Tepp WH, Johnson EA, et al. Persistence of botulinum neurotoxin a subtypes 1-5 in primary rat spinal cord cells. Plos One. 2014;9:e90252.
153. Shoemaker CB, Oyler GA. Persistence of botulinum neurotoxin inactivation of nerve function. Curr Top Microbiol Immunol. 2013;364:179–196.
154. Toth S, Brueggmann EE, Oyler GA, et al. Tyrosine phosphorylation of botulinum neurotoxin protease domains. Front Pharmacol. 2012;3:102.
155. Conway JO, Sherwood LJ, Collazo MT, et al. Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents. Plos One. 2010;5:e8818.
156. Meunier FA, Schiavo G, Molgo J. Botulinum neurotoxins:from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris. 2002;96:105–113.
157. Juzans P, Comella JX, Molgo J, et al. Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle. Neuromus Dis. 1996;6:177–185.• This article describes the remarkable remodeling of nerve terminals caused by BoNTs intoxication.
158. Harrison AR, Berbos Z, Zaldivar RA, et al. Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle. Invest Ophthal Vis Sci. 2011;52:982–986.
159. Jin L, Pan L, Liu W, et al. IGF-1 antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength. Int J Mol Sci. 2013;14:9051–9061.• This paper shows that the duration of BoNT effects can be mitigated by interfering with factors released by muscle as a consequence of paralysis.
160. Jablonka S, Holtmann B, Sendtner M, et al. Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease. Exp Neurol. 2011;232:261–269.
161. Adler M, Scovill J, Parker G, et al. Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon. 1995;33:527–537.
162. Friggeri A, Marçon F, Marciniak S, et al. 3,4-Diaminopyridine may improve neuromuscular block during botulism. Critical Care. 2013;17:449.
163. Zakhari JS, Kinoyama I, Hixon MS, et al. Formulating a new basis for the treatment against botulinum neurotoxin intoxication:3,4-diaminopyridine prodrug design and characterization. Bioorg Med Chem. 2011;19:6203–6209.
164. Pellett S. Progress in cell based assays for botulinum neurotoxin detection. Curr Top Microbiol Immunol. 2013;364:257–285.
165. Kiris E, Kota KP, Burnett JC, et al. Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discovery. Expert Rev Mol Diagn. 2014;14:153–168.
166. Pearce LB, Borodic GE, First ER, et al. Measurement of botulinum toxin activity:evaluation of the lethality assay. Toxicol Appl Pharmacol. 1994;128:69–77.
167. Hakami RM, Ruthel G, Stahl AM, et al. Gaining ground:assays for therapeutics against botulinum neurotoxin. Trends Microbiol. 2010;18:164–172.